ClinicalTrials.gg

Program

NM-101

A development code.

Its studies are mostly in Parkinson Disease, led by Neuramedy.

Furthest: phase 1, since Mar 6, 20232 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Neuramedy21 open or runningphase 1since Mar 6, 2023Mar 6, 2023none ahead

Also a collaborator on its studies: quotient-sciences.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 6, 2023First study: phase 1 study in Parkinson DiseaseFirst studyNCT05790382 · 56 enrolled · United Kingdom
  2. Apr 3, 2025Phase 1 study in Healthy SubjectsNCT06934941 · 36 planned · Korea, Republic of

TargetBeta

TLR2 →read by rule
“NM-101 is an anti-TLR2 antibody which may have clinical efficacy in Parkinson's disease patients.”study text, by rule · the study

Other programs on TLR2

ProgramCompanyFurthest phaseStudies
INNA-051ruleena-respiratory-pty-ltdphase 23

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06934941Healthy Subjects · Korea, Republic of1RecruitingOct 30, 202536
NCT05790382Parkinson Disease · United Kingdom1UNKNOWNMay 30, 202456

How it is read

Names in the registry

  • “NM-101”, 2 entries

Codes read as this program: NM101.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.